Boston Scientific Corp (NYSE:BSX) shows strong technical and growth momentum, meeting Minervini Trend Template criteria with solid earnings and revenue expansion. A potential breakout candidate for growth investors.
Boston Scientific Corp (NYSE:BSX) shows strong technicals and a high-quality setup, making it a breakout candidate. The stock's consolidation near resistance and institutional support suggest potential upside.
BOSTON SCIENTIFIC CORP (NYSE:BSX) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has solid EPS growth, margin expansion, and a bullish consolidation pattern.
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Boston Scientific Corp (NYSE:BSX) shows strong technical and fundamental growth, fitting Minervini’s trend template with high earnings momentum and improving margins. A top pick for momentum investors.
Boston Scientific Corp (NYSE:BSX) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has solid support levels and consolidation patterns ahead of a potential breakout.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Boston Scientific Corp (NYSE:BSX) combines strong earnings momentum, expanding margins, and a bullish technical setup, making it a candidate for high-growth investors.
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital.
The select few that can do all three for many years are often the ones that make you life-changing money.
The company said in a regulatory filing that the decision was made in light of increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new regions.
Boston Scientific Corp (NYSE:BSX) shows strong growth fundamentals and a bullish technical setup, making it a compelling candidate for growth investors.
